The Role of Platelet Activating Factor in Airway Hyperresponsiveness by Ilyas, Mohammad
 
 
 
 
 
 
 
https://theses.gla.ac.uk/ 
 
 
 
 
Theses Digitisation: 
https://www.gla.ac.uk/myglasgow/research/enlighten/theses/digitisation/ 
This is a digitised version of the original print thesis. 
 
 
 
 
 
 
 
 
Copyright and moral rights for this work are retained by the author 
 
A copy can be downloaded for personal non-commercial research or study, 
without prior permission or charge 
 
This work cannot be reproduced or quoted extensively from without first 
obtaining permission in writing from the author 
 
The content must not be changed in any way or sold commercially in any 
format or medium without the formal permission of the author 
 
When referring to this work, full bibliographic details including the author, 
title, awarding institution and date of the thesis must be given 
 
 
 
 
 
 
 
 
 
 
 
 
 
Enlighten: Theses 
https://theses.gla.ac.uk/ 
research-enlighten@glasgow.ac.uk 
T h e  R o le  o f  P la telet  A c t iv a t in g  Fa c t o r  in  
A ir w a y  H y p e r r e s p o n s iv e n e s s
by
Dr MOHAMMAD ILYAS
M.B.B.S.(Pesh), D.T.C.D.(Wales) 
M.R.C.P.(U.K)
A thesis submitted to the 
University of Glasgow 
in candidature for the degree of 
Master of Science 
in the 
Faculty of Medicine
Department of Respiratory Medicine, 
Western Infirmary, Glasgow, U.K. 
November, 1991.
ProQuest Number: 10992233
All rights reserved
INFORMATION TO ALL USERS 
The quality of this reproduction is dependent upon the quality of the copy submitted.
In the unlikely event that the author did not send a com p le te  manuscript 
and there are missing pages, these will be noted. Also, if material had to be removed,
a note will indicate the deletion.
uest
ProQuest 10992233
Published by ProQuest LLC(2018). Copyright of the Dissertation is held by the Author.
All rights reserved.
This work is protected against unauthorized copying under Title 17, United States C ode
Microform Edition © ProQuest LLC.
ProQuest LLC.
789 East Eisenhower Parkway 
P.O. Box 1346 
Ann Arbor, Ml 48106- 1346
GLASGOW
UNIVERSITY
LIBRARY
Q S o '!
SUMMARY
This thesis consists of two parts , the first part is a study of the effects of 
inhaled PAF on the bronchial airway responsiveness . PAF also activates 
eosinophils to release major basic proteinsincluding eosinophil cationic 
protein(ECP) which when measured in the bronchial lavage fluid can 
provide an indirect assessment of airway damage. The second part of the 
project is concerned with whether serum levels of ECP can also be 
correlated with airway damage.
We have examined the effect of inhaled PAF(96 ug) on the 
bronchial airway responsiveness to methacholine at day 1, day 3 and day 7 
after PAF challenge, in 6 nonatopic (mean age 29.7 yrs) and seven atopic 
(mean age 29.3 yrs) healthy volunteers.
After PAF inhalation, plasma ECP levels (ug/1) were measured over 
a 3 hour period using a Pharmacia radioimmunoassay.
PAF challenge and methacholine responsiveness i/v^  repeated on 2 
occasions allowing at least 4 weeks between cycles. Airway responses were 
assessed by measuring specific airways conductance (SGaw) in a constant 
volume body plethysmograph. The maximum mean(sem) % falls in 
SGaw in the 1st, 2nd and 3rd PAF challenge in nonatopic subjects were 
47(8.7), 49.5(9.3) and 47.2(6.3) respectively and in atopic subjects 41.7(6.2), 
48.0(6.1) and 49.3(6.3) respectively. The changes in SGaw were comparable 
in 3 cycles in both groups. The geometric mean PC 35 SGaw to 
methacholine was 6.51 m g/m l in nonatopic and 0.99 m g/m l in atopic 
subjects before PAF inhalation. PAF did not significantly alter the mean 
PC35 SGaw in either group. One subject did show >2 fold decrease in PC35 
SGaw but this was not reproducible in other cycles.
In the second part of the project, the effect of PAF challenge on 
serum ECP level was compared in nonatopic and atopic subjects. Seven 
nonatopic and eight atopic subjects participated in this study. Blood was 
collected for three hours post PAF challenge for ECP assay. The mean
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(sem)serum eosinophil cationic protein (ECP) level in nonatopic subjects 
before PAF challenge was 8.3 (3.6) ug/L, while at 15, 30, 60, 120, and 180 
minutes post PAF challenge the levels were 5.4 (2.1), 5.6(1.3), 5.7(1.2), 
5.6(1.2), and 4.6(0.97)ug/L respectively. There was no statistically significant 
difference before and after PAF challenge in the serum ECP levels. Among 
the atopic subjects the mean(sem) ECP level before PAF challenge was 
4.9(0.7) while at 15, 30, 60, 120, and 180 minutes post PAF challenge the 
mean levels were 3.5(1.0), 4.6(0.7), 4.2(0.7), 4.6(0.8) and 4.6(0.9) ug/L  
respectively. There was no statistically significant difference in serum ECP 
level before and after PAF challenge. Our results suggest that PAF is a 
potent bronchoconstrictor but it does not induce airway 
hyperresponsiveness in either nonatopic or atopic subjects. Although PAF 
inhalation may activate airway eosinophils in both atopic and nonatopic 
subjects, it does not produce a rise in the plasma ECP levels.
3
TABLE OF CONTENTS
A Summary....................................................................................................2
Table of Contents..........................................................................................4
Index of Tables...............................................................................................6
Index of Figures.............................................................................................8
Acknowledgement..................................................................................... 11
Author declaration..................................................................................... 12
PART ONE 
Chapter 1
1.1 Historical background of Asthma........................................14
1.2 Definition of Asthma............................................................. 15
1.3 Bronchial Hyperresponsiveness............................................17
1.4 Mediators in Asthma............................................................22
L4»l Histamine...........................................................................22
1.4.2 Leukotrienes..............................................................22
1.4.3 Prostaglandins & Cytokines...................................... 23
1.4.4 Platelet Activating Factor......................................... 24
Chapter 2
2.1 Introduction of Platelet Activating Factor........................... 25
Chapter 3
Main Aims of Project...........................................................28
3.1 Brief Summary...................................................................... 29
3.2 Subjects....................................................................................29
3.3 Challenge Material & Methods............................................. 30
4
3.3.1 Methacholine............................................................. 30
3.3.2 Nebuliser...................................................................30
3.3.3 PAF & Inhalation.......................................................31
3.3.4 Specific Airway Conductance & Body
Plethysmograph........................................................ 31
3.4 Protocol and Method..............................................................32
3.5 Statistical Analysis.................................................................33
3.6 Results.................................................................................... 33
3.6.1 Bronchoconstriction...................................................33
3.6.2 Bronchial Hyperresponsiveness...............................34
3.6.3 Whether Bronchial Airway
Hyperresponsiveness is Reproducible.................... 35
3.7 Discussion................................................................................35
PART TWO
Chapter 4
The Effect of PAF Challenge on Serum Eosinophil cationic Protein (ECP) 
in Nonatopic and Atopic Subjects.
4.1 Introduction...........................................................................39
4.2 Subjects detail........................................................................ 41
4.3 M ethod................................................................................... 41
4.3.1 Reagents.................................................................... 42
4.3.2 Test Procedure.......................................................... 42
4.3.3 Working Steps.......................................................... 42
4.4 Results.................................................................................... 43
4.5 Discussion............................................................................... 43
Appendix..................................................................................................... 45
Tables and Figures  i - xiiv
Abbreviations.............................................................................................. 46
References.................................................................................................... 48
5
INDEX OF TABLES
1.0 Demographic data of atopic subjects................................................. i
2.0 Demographic data of nonatopic subjects.........................................ii
3.0 Detail about Protocol for PAF study................................................iii
4.0 Mean maximum percentage fall in SGaw from post 
saline baseline after PAF challenge in atopic
subjects..............................................................................................iv
5.1 Mean baseline SGaw Methacholine in nonatopic
subjects on study days of the first cycle........................................... v
5.2 Mean baseline SGaw Methacholine in nonatopic
subjects on study days of the second cycle..................................... vi
5.3 Mean baseline SGaw Methacholine in nonatopic
subjects on study days of the third cycle....................................... vii
6.0 Mean maximum percentage fall in SGaw from post 
saline baseline after PAF challenge in nonatopic
subjects........................................................................................... viii
7.1 Mean baseline SGaw Methacholine in atopic
subjects on study days of the first cycle........................................... ix
7.2 Mean baseline SGaw Methacholine in atopic
subjects on study days of the second cycle.......................................x
7.3 Mean baseline SGaw Methacholine in atopic
subjects on study days of third cycle................................................xi
8.1 PC35 SGaw Methacholine before and after PAF 
challenge in nonatopic subjects on study days of the
first cycle...........................................................................................xii
8.2 PC35 SGaw Methacholine before and after PAF 
challenge in nonatopic subjects on study days of the
second cycle................................................ ;................................... xiii
8.3 PC35 SGaw Methacholine before and after PAF 
challenge in nonatopic subjects on study days of the
third cycle........................................................................................xiv
9.1 PC35 SGaw Methacholine before and after PAF
challenge in atopic subjects on study days of the first 
cycle...................................................................................................xv
6
9.2 PC35 SGaw Methacholine before and after PAF 
challenge in atopic subjects on study days of the
second cycle.................................................................................... xvi
9.3 PC35 SGaw Methacholine before and after PAF 
challenge in atopic subjects on study days of the
third cycle...................................................................................... xvii
10 Serum eosinophil cationic protein (ECP) levels in 
non-atopic subjects before and after PAF challenge.................xviii
11 Serum eosinophil cationic protein (ECP) levels in
atopic subjects before and after PAF challenge............................ xix
12 Mean baseline SGaw and PC35 SGaw Methacholine 
before and after PAF challenge in nonatopic
subjects on study days of the three cycles.......................................xx
13 Mean baseline SGaw and PC35 SGaw Methacholine 
before and after PAF challenge in atopic subjects on
study days of the three cycles......................................................... xxi
7
INDEX OF FIGURES
(in the text)
1.0 Airway hyperresponsiveness.................................................
2.0 Diagrammatic representation of platelet activating 
factor (PAF), illustrating the location of the ether 
bond (position 2). Modification of the molecule at 
either of these carbon atoms results in reduction or
loss of biological activity.........................................................
3.0 Interaction of PAF with its putative receptor site
results in activation of membrane associated 
phospholipase C, leading to stimulation of the 
phosphotidylinositol (PI) cycle....................................................... .
(in the Appendix)
4.0 Mean maximum percent fall in SGaw after PAF 
challenge in each of the three cycles in nonatopic
subjects........................................................................................... xxii
5.1 Mean baseline SGaw in nonatopic subjects on study
days of the first cycle.....................................................................xxiii
5.2 Mean baseline SGaw in nonatopic subjects on study
days of the second cycle................................................................xxiv
5.3 Mean baseline SGaw in nonatopic subjects on study
days of the third cycle.................................................................... xxv
6.0 Mean maximum percentage fall in SGaw after PAF 
challenge in each of the three cycles in atopic
subjects...........................................................................................xxvi
7.1 Mean baseline SGaw in atopic subjects on study
days of the first cycle................................................................... xxvii
7.2 Mean baseline SGaw in atopic subjects on study
days of the second cycle............................................................. xxviii
7.3 Mean baseline SGaw in atopic subjects on study
days of the third cycle................................................................... xxix
8
8.1 PC35 SGaw Methacholine before and after PAF
challenge in nonatopic subject (JM) in the three
cycles............................................................................................... xxx
8.2 PC35 SGaw Methacholine before and after PAF 
challenge in nonatopic subject (JJ) in the three
cycles.............................................................................................. xxxi
8.3 PC35 SGaw Methacholine before and after PAF
challenge in nonatopic subject (EH) in the three
cycles.............................................................................................xxxii
8.4 PC35 SGaw Methacholine before and after PAF 
challenge in nonatopic subject (CO) in the three
cycles............................................................................................xxxiii
8.5 PC35 SGaw Methacholine before and after PAF
challenge in nonatopic subject (DS) in the three
cycles............................................................................................xxxiv
8.6 PC35 SGaw Methacholine before and after PAF
challenge in nonatopic subject (MI) in the three
cycles............................................................................................. xxxv
9.1 PC35 SGaw Methacholine before and after PAF 
challenge in atopic subject (CJ) in the three cycles.................xxxvi
9.2 PC35 SGaw Methacholine before and after PAF 
challenge in atopic subject (SM) in the three cycles............. xxxvii
9.3 PC35 SGaw Methacholine before and after PAF 
challenge in atopic subject (MM) in the three cycles...........xxxviii
9.4 PC35 SGaw Methacholine before and after PAF 
challenge in atopic subject (JS) in the three cycles..................xxxix
9.5 PC35 SGaw Methacholine before and after PAF 
challenge in atopic subject (MW) in the three
cycles...................................................................................................xl
9.6 PC35 SGaw Methacholine before and after PAF 
challenge in atopic subject (CR) in the three cycles.................... xli
9.7 PC35 SGaw Methacholine before and after PAF 
challenge in atopic subject (LM) in the three cycles.
9
10 Serum eosinophil cationic protein (ECP) levels in
non-atopic subjects before and after PAF inhalation................. xlii
11 Serum eosinophil cationic protein (ECP) levels in 
atopic subjects before and after PAF inhalation...xliii
10
ACKNOWLEDGEMENTS
I wish to acknowledge my gratitude to Dr.K.R.Patel, Consultant Physician 
in Respiratory Medicine and to Professor John Reid, Professor of Medicine 
and Therapeutics , Western Infirmary Glasgow. The former encouraged 
and guided me throughout my research project and the latter inspired me 
with full zeal towards this study. I am also grateful to Dr S. K. Ghosh, who 
stimulated my interest in research work, and to rest of the Medical Staff 
who has been very helpful. I also wish to thank Dr Kennedy R. Lee 
Lecturer in Clinical Pharmacology who also kindly agreed to supervise my 
work.
The work described in this thesis was carried out while I was 
working as a Research Fellow in the Department of Respiratory Medicine , 
Western Infirmary Glasgow. Most of the work was done in the Respiratory 
Department. Part of the work, involving measurement of serum 
eosinophil cationic protein levels (ECP), was carried out in the department 
of Immunology, Western Infirmary Glasgow. I am also grateful to Dr C. 
McSharry for analysing the blood for ECP levels.
I wish to thank Mrs. Rita Jack and her colleagues in the Respiratory 
Laboratory, for the care and enthusiasm they showed in the work. Finally , 
I must thank all those who volunteered to participate, specially to 
mention the technical staff of Cardiology and Respiratory Departments 
Western Infirmary Glasgow, who took part in the experimental work 
described in the thesis.
11
AUTHOR DECLARATION
I hereby declare that this thesis "The Role of Platelet Activating Factor in 
Airway Hyperresponsiveness", is part of the on-going work on platelet 
activating factor which is being carried out in the Department of 
Respiratory Medicine, Western Infirmary, Glasgow. The thesis has been 
composed by myself under the supervision of Dr. K. Patel, Consultant 
Physician in Respiratory Medicine and a Honorary Senior Lecturer to the 
University of Glasgow. I also declare that this work has not been submitted 
in any previous application for degree. The work has been carried out by 
myself and the General methods and Composition were discussed with 
my supervisor beforehand. I also acknowledge my thanks to all sources of 
information which h e lp ^ e  in my work.
Dr. Mohammad Ilyas
M.B.B.S. (Pesh), D.T.C.D. (Wales), 
M.R.C.P. (U.K.) 
Research Fellow 
Respiratory Medicine 
Western Infirmary Glasgow.
12
PART ONE
13
CHAPTER ONE.
ASTHMA
1.1 HISTORICAL BACKGROUND.
Asthma is one of the classic diseases recognised by Hippocrates over 2,000 
years ago. Aretaeus (81-138 AD), and Galen (139-199 AD) used the term 
asthma to describe any condition associated with dyspnoea. The great 
mediaeval physician Maimonides (1135-1204), in the Treatise of Asthma 
(1190)(1), also tended to confuse asthma with other pulmonary disorders. 
Nearer to the time of Floyer, Jean Baptiste van Helmont (1597-1644) and 
Thomas Willis (1621-1675) had distinguished asthma from other varieties 
of dyspnoea, but they regarded the condition as a kind of nervous or 
convulsive fit akin to epilepsy. It was Sir John Floyer(2) who clearly 
defined asthma (derived from 'Greek* meaning breathless), separating it 
from other pulmonary disorders. He also considered the cause of dyspnoea 
was bronchial constriction, due to spasm and he regarded the spasm to be 
tonic, more akin to catalepsy than to the clonic convulsion of epilepsy.
It is noteworthy that Floyer was able to achieve this merely by 
careful clinical observation alone. Though his galenic ideas of 
pathogenesis and medical treatment do not stand up to modern inquiry , 
nevertheless he was familiar with the multifactorial basis of asthma i.e. 
heredity, occupation, exercise, and psychological influences. The 
importance of Floyer's work was also appreciated by later writers on 
asthma, e.g., John Millar(1735-1805) in 1769(3). Later on Henry Salter (an 
asthma sufferer ,1823-71) in his book on Asthma : Its Pathology and 
treatment(4) defined asthma as 'Paroxysmal dyspnoea of a peculiar 
character , generally periodic with intervals of healthy respiration between 
attacks.
The condition from which Floyer and Salter suffered is so distinct 
that it may be diagnosed by non-medical people, and its name is used in 
common place. The common denominator underlying asthmatic
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diathesis is a non-specific hyperresponsiveness of the tracheobronchial 
tree. This increased airway bronchial responsiveness can be familial or 
acquired and is materially worsened by events that promote airway 
inflammation. The stimuli that increase airway responsiveness and incite 
acute episodes of asthma can be grouped into seven major categories : 
allergic, pharmacological, environmental, occupational, infectious, 
exercise related, and emotional.
1.2 DEFINITION OF ASTHMA
Asthma is defined as a disease characterised by periodicity of symptoms of 
cough and wheezing, reversible obstructive ventilatory defect and 
increased airway responsiveness (5). The changes in severity of airway 
narrowing can occur spontaneously or as a result of therapy, and my be 
measured by forced expiratory volume in the first second (FEV1), peak 
expiratory flow rate per minute(PEF), airway resistance (Raw), or specific 
airway conductance(SGaw). In addition asthmatic subjects show an 
increased responsiveness of the tracheobronchial tree to a variety of 
antigenic stimuli(6).
The airway narrowing that occurs in asthma is intermittent and 
variable. Complete remission can occur in between attacks, although some 
abnormality of function is often detectable with sensitive tests(7). During 
attacks, widespread narrowing of bronchi results in diffuse wheezing, 
often associated with dyspnoea, even at rest. Although the reversibility of 
airway may be suspected from the history, it should always be evaluated 
objectively by measurement of airway function after administration of a 
bronchodilator(8). Asthma can generally be divided into two major 
categories, extrinsic and intrinsic, but there may be some overlap between 
the two.
1.2.1 EXTRINSIC ASTHMA
Extrinsic asthma occurs in patients who are atopic, a term used to describe 
a genetic predisposition to respond to antigenic challenge with the
15
formation of immunoglobulin antLbody of IgE type. The inheritance is 
complex but usually incomplete, increasing greatly if both parents are 
atopic. For example , of 13 children born of two allergic parents, 11 
developed atopy over a 4 years follow up period.Viral upper respiratory 
tract infections frequently predated the onset of allergic manifestations, 
suggesting that interaction of viral infection with genetic predisposition 
may be important(9).
The prevalence of atopy increases until approximately age 20, when 
it gradually declines. Peak IgE levels occur at age 14. In infants and young 
children, atopy and asthma are twice as common in males as in females 
(10, 11). Besides demonstrating increased blood IgE levels, atopic 
individuals are characterised by immediate skin test responses to a variety 
of antigens and a high incidence of eczema, rhinitis and asthma. However, 
atopy is not synonymous with asthma.The former occurs in 30 per cent of 
population, whereas the incidence of asthma is less than 5 per cent. 
Although affected identical twins invariably develop atopy, their allergic 
m anifestations and non-specific bronchial responsiveness are 
discordant(12, 13). Patients with extrinsic or atopic asthma are 
distinguished by ,(a) family history, (b) onset in the first three decades of 
life, (c) seasonal symptoms, (d) elevated blood levels of IgE and (e) positive 
skin and bronchial challenge tests to specific allergens (13).
1.2.2 INTRINSIC ASTHMA
Intrinsic asthma refers to patients in whom atopy or specific external 
triggers of bronchoconstriction cannot be identified. The term intrinsic 
was initially coined because it was believed that these patients were 
responding to antigens free microbial agents released in their 
tracheobronchial tree. Patients with intrinsic asthma are characterised by : 
(a) being of elder age group, (b) having no family history of asthma or 
allergic diseases, (c) an absence of elevated blood levels of 
immunoglobulin IgE, or positive skin or bronchial responses to allergen 
challenge, (d) increased blood and sputum eosinophil counts, (e)
16
responsiveness to therapy and (f) a tendency to persistent progressive 
diseases resulting in fixed airflow obstruction (14,15).
Exercise induced asthma is not a separate category because the 
majority of patients with asthma develop bronchoconstriction during 
exercise. It is believed that the stimulus for exercise induced asthma is not 
exercise but the cooling or drying of the airway mucosa that occurs on 
inhalation of incompletely conditioned air.
In some patients exposure to a specific external agent can be clearly 
shown to be the cause of reversible bronchoconstriction and there is no 
tendency for excessive IgE production. Patients in this category are known 
to suffer from occupational (16) asthma.
1.3 BRONCHIAL HYPERRESPONSIVENESS.
Bronchial hyperresponsiveness is considered by some as a sine qua non of 
asthma (17). The nonspecific bronchial hyperresponsiveness represents 
the exaggerated airway narrowing that occurs in response to inhalation of 
a variety of non-allergenic, usually pharmacologic, stimuli(18). Although 
all the stimuli used to demonstrate bronchial hyperresponsiveness result 
in some degree of narrowing in normal subjects, it is the excessive 
narrowing at very much lower dose or concentration that characterises 
nonspecific bronchial hyperresponsiveness. Exaggerated bronchial 
narrowing in response to pharmacologic agents was described many years 
ago, but only during the last 10 years, has the importance of nonspecific 
bronchial hyperresponsiveness, been recognised and techniques to 
demonstrate and quantify it, been developed. In 1921 Alexander and 
Paddock reported that pilocarpine resulted in asthmatic breathing in 
asthmatic patients , but not in normal subjects. They also observed 
exaggerated vagal effects such as salivation and sweating, and suggested 
that asthma might be secondary to increased vagal tone. In 1929 and 1932, 
Weiss and his associates demonstrated a decrease in vital capacity in 
response to intravenous histamine in emphysematous and asthmatic 
subjects at a concentration that had no effect on normal subjects (19, 20). In
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1949, Curry (21) administered histamine and acetylcholine by both inhaled 
and intravenous routes to normal subjects and patients with rhinitis and 
asthma.In addition to showing an exaggerated response in asthmatics, he 
demonstrated concordance of the response to both agents and was 
therefore the first to note the nonspecific natu re  of the 
hyperresponsiveness. Despite these important advances it was Tiffeneau 
in the 1950s who first recognised the potential importance of nonspecific 
bronchial hyperresponsiveness and who systematically and quantitatively 
began to study nonspecific bronchial hyperresponsiveness in patients with 
asthma and allergic rhinitis, employing acetylcholine and histamine as 
provocative agents (22). Since the mid 1970s, interest in nonspecific 
bronchial hyperresponsiveness has increased dramatically and the 
condition has been discussed extensively in the literature (23, 24). Its 
nonspecific nature has become increasingly recognised and the list of 
substances to which asthmatics respond excessively is continually 
enlarging. The pharmacological agents include histamine, pilocarpine, 
m ethacholine, carbachol, acetylcholine, serotonin, bradykinin, 
prostaglandin F2a, leukotriene C4, D4, adenosine (25, 26) and platelet 
activating factor. Asthmatics also show excessive airway narrowing in 
response to inhalation of atmospheric pollutants, dusts cold, dry air and to 
certain respiratory manoeuvres such as deep inspiration or forced 
expiration.
The fact that nonspecific bronchial hyperactivity is such a 
characteristic feature of asthma raises the question of whether it represents 
a basic defect in the control of bronchial calibre that precedes and 
predisposes to the development of asthma, or that it is a consequence of it. 
The demonstration that the bronchomotor response to pharmacological 
agents by various nonasthmatic animal species as well as man is highly 
variable raises the possibility that the exaggerated airway narrowing in 
asthmatics simply represents one end of a wide biological susceptibility (27, 
28, 29). Certain canine species such as the Basenji-greyhounds exhibit 
markedly increased nonspecific bronchial hyperresponsiveness(30), 
whereas some strains of rats can be bred to manifest exaggerated 
bronchoconstriction(31).Also a percentage of clinically healthy first degree
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relatives of children with asthma demonstrate nonspecific bronchial 
hyperresponsiveness (10). These observations support the concept that a 
genetically determined airway responsiveness might predispose to 
asthma. However studies of monozygotic and dizygotic twins have shown 
similar inter-twin variability of response to methacholine, supporting the 
possible role of environmental factors as determinant of nonspecific 
hyper-responsiveness (32).
Non-specific bronchial hyperresponsiveness is not a static 
phenomenon, an individual’s responsiveness can change considerably 
with the duration of exposure to infectious agents (33), environmental 
pollutants (34), and specific antigens or sensitising agents (35). For example 
in a group of patients with occupational asthma secondary to western red 
cedar exposure, nonspecific airway responsiveness decreased gradually 
over a period of months following cessation of exposure and increased 
again following re-exposure (36).
Non-specific bronchial hyperresponsiveness is so characteristic of 
asthma that it is questionable whether a diagnosis can be made in its 
absence(17). Rarely , patients with occupational asthma or non- 
occupational allergic asthma do not show increased nonspecific bronchial 
hyperresponsiveness at the time of diagnosis, but develop increased 
responsiveness with prolong exposure (37-40). Although nonspecific 
bronchial hyperresponsiveness is virtually 100 per cent sensitive in the 
diagnosis of asthma, it is far from being specific for example, it has been 
demonstrated in patients with sarcoidosis(41), extrinsic allergic 
alveolitis(42, 43) and chronic obstructive airway disease(44, 46, 47). 
Although in these condition it appears to be related to a baseline decrease 
in airway calibre(40, 41). In a comparison study of patients with asthma 
and chronic obstructive airway disease, nonspecific bronchial airway 
hyperresponsiveness was found to be unrelated to baseline forced 
expiratory volume in one second (FEV1) in the former but to be 
significantly related to pre challenge forced expiratory volume in one 
second (FEV1) in the latter(45). Similarly, in occupational surveys of 
airway responsiveness, the incidence of nonspecific bronchial
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hyperresponsiveness is higher than that of clinically diagnosed asthma, 
suggesting an appreciable false positive rate (39).
Bronchial hyper-reactivity is quantified by measuring the dose or 
concentration of inhaled histamine or methacholine that causes a 20 per 
cent decrease in FEV1 . Rather than being a congenital defect that increases 
the risk of developing asthma, nonspecific bronchial hyperresponsiveness 
is probably an acquired abnormality;however its exact pathogenesis 
remains unknown. The most plausible theory is that it is a consequence of 
the chronic inflammatory reactions in the airway mucosa of asthmatic 
patients. Inflammation may cause hyperresponsiveness by epithelial 
damage, excessive mediator release, loss of a putative epithelial derived 
relaxing factor (EpDRF), increasing airway permeability leading to oedema 
and airway wall thickening and by altering the amount and contractility of 
airway smooth muscle (see Figure 1).
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Figure 1
A n t ig e n  N o n s p e c i f i c  stimuli
i x i
Neutrophil M ast cell M acro p h a g e  T ly m p h o cy te  P latelet
Eosinophil
Epithelial  d a m a g e
j P e r m e a b i l i t y  L o s s  of E pD R F 1 L oss  of m ed ia to r  N eu ra l
d e g r a d i n g  e n z y m e s  rellex
M e d ia to r s
Airway hyperresponsiveness
EpDRF: a putative epithelial derived relaxant factor
Cellular interactions leading to eosinophil infiltration and 
epithelial injury. (reproduced from Asthma: Basic Mechanisms
and Clinical Management. Editors Barnes PJ, Rodger IW & 
Thomson NC. Academic Press, London, 1988; p.430 with authors 
permission)
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1.4 MEDIATORS IN ASTHMA.
Many mediators have been implicated in asthma. Several can produce 
many of the features suggestive of asthma including; smooth muscle 
contraction, mucus hypersecretion, extravasation of plasma leading to 
bronchial oedema and inflammatory cell chemotaxis.
The complex interaction between many mediators may potentiate their 
effect, thus antagonism of a single mediator is unlikely to result in 
significant clinical improvement.
1.4.1 HISTAMINE
Histamine is released from airway mast cells and may have several local 
effects. It was first to be observed by Dale and Laidlaw in 1911 (48) as a 
potent vasoactive substance but its capacity to induce asthma was first 
noted by Weiss in 1929 (46) and described in more detail by Curry in 1946 
(21). Histamine can cause bronchial obstruction by a direct effect on airway 
smooth as well as through vagal reflex action, neuropeptide release and 
potentiation of adrenergic responses. It also increases mucus secretion and 
causes oedema of the airway by increased permeability. The actions of 
histamine are mediated through two distinct receptors, HI and H2, 
defined by the action of their respective agonist and antagonist. It is the HI 
receptor which causes increased contractility of muscle, vascular 
permeability and prostaglandin generation and activation of airway vagal 
afferent nerves. Although anti-histamines are not useful in the treatment 
of asthma, but specific HI antagonists such as terfenadine and cetirizine 
have certainly been shown to cause bronchodilation(49).
1.4.2 LEUKOTRIENES
Leukotrienes are derived from arachidonic acid by the action of 
lipoxygenase. The substances that fulfil the functional characteristics of 
slow releasing substance-A (SRS-A) are the leukotrienes C4, D4 and E4 
(LTc4, LTD4 and LTE4). They are produced by mast cells, macrophages and
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eosinophils and cause . bronchial smooth contraction, increased
vascular permeability and increased mucus production (50, 51). 
Leukotrienes C4 and D4 are potent bronchoconstrictors of the airways 
while LTB4 is a powerful chemotaxin and can attract both eosinophils and 
neutrophils to the site of its release(52). When administered by inhalation 
to human subjects leukotrienes cause dose dependent narrowing that is 
maximum at 3 minutes and resolves over 1 to 3 hours i.e., longer than 
that produced by histamine(53).
1.4.3 PROSTAGLANDINS
Prostaglandins PGD2, PGF2a and thromboxane are bronchoconstrictors 
produced from arachidonic acid by the action of cyclo-oxygenase in several 
inflammatory cells (mast cells, macrophages, eosinophils). However, the 
inhibition of this enzyme by aspirin and other non-steroidal anti 
inflammatory drugs has no clear beneficial effect in asthma, (54) in fact in 
approximately 3% of cases the asthma worsens.
OTHER MEDIATORS.
Bradykinin is an inflammatory peptide formed by the action of 
kininogenase and kallikrein on a plasma precursor. It acts as a potent 
bronchoconstrictor in asthmatics, probably by activating airway sensory 
nerves which are sensitized by inflammatory reaction.
Cytokines are peptide mediators released from several types of 
inflammatory cells (lymphocytes, macrophages, mast cells) which may be 
involved in coordinating the chronic inflammatory process in asthma. 
Similarly neutrophil chemotactic factor of anaphylaxis (NCFA)(55) and 
eosinophillic factor of anaphylaxis (ECFA) (55) and eosinophillic factor of 
chemotaxins derived from lipoxygenase metabolism of arachidonic acid 
may be important in the induction of late asthmatic response.
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1.4.4 P.A.F..
Platelet activating factor (PAF) has recently assumed an important role in 
the pathogenesis of asthma (57), particularly because PAF has been 
demonstrated to increase nonspecific bronchial hyperresponsiveness in 
animals (58), and humans (59, 60).
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CHAPTER TWO.
2 .1 PLATELET ACTIVATING FACTOR.
Platelet Activating Factor (PAF), is a biologically active phospholipid 
mediator with potent inflammatory properties. It is derived from 
eosinophils (61), neutrophils (62), macrophages (63), basophils (64), 
endothelial cells (65) and platelets (66). It has been reported to possess 
many pharmacological actions pertinent to asthma, such as 
bronchoconstriction, non-specific bronchial airway hyperresponsiveness 
and increased capillary permeability with chemotactic stimulation of 
inflammatory cells infiltration.
The chemical structure of PAF was identified in 1979 by three independent 
groups as l-O-alkyl-2-acetyl-sn-glyeery 1-3-phosphorylcholine (67) (Fig 2). 
The active material is referred to as PAF-acether. Each feature of the 
structure is important for its optimal activity. The presence of ether 
linkage at position 1 and the length of alkyl side chain are critical 
determinants for biological activity, whereas the alkyl side chain at 
position 2 of the molecule is less critical. PAF derived from biological 
origin, including human skin (68) is a mixture of mainly Cl 6 and C l8 
types (69). The biological activity of C16 PAF and C18 PAF do not appear to 
be qualitatively or quantitatively different.
Human eosinophils (61) and alveolar macrophages (63) which are 
extremely good sources of PAF, release PAF in response to activation by an 
IgE-dependent mechanism. Alveolar macrophages and eosinophils have 
IgE receptors on their surface and these cells are present in the airways of 
asthmatics and are activated following antigen provocation in sensitised 
asthmatics (70). Human : .. are reported to be heterogeneous
consisting of normal density and light density cells that differ in their 
functional and morphological properties (71). The light density cells (rich 
in PAF) that are found in patients with an eosinophilia are generally 
regarded as being more activated than normal density cells (72).
The molecular mechanism by which PAF produces its various effect on 
target cells is still debated, but stereoselectivity of its effects, its high 
biological potency and development of tachyphylaxis, all suggest that 
membrane receptors are involved and a putative structure of the binding
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Figure 2 Diagrammatic representation of plate let-activating factor (PAF), 
illustrating the location of the ether bond (position 1) and 
the acetyl side chain (position 2). Modification of the molecule 
at either of these carbon atoms results in reduction or loss 
of biological acitvity.
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site for PAF can be put forward (Fig 3). These receptors have been described 
in platelets (73), neutrophils (74), macrophages (75) and lung tissue (76). 
Valone et al. have isolated a PAF binding receptor from hum an platelets 
which appears to be protein (77). Howang et al found out that the rank > 
order of potency for several antagonists was different in human 
neutrophils and platelets and that monovalent cations had different 
effects on binding to the two cells. From Hwang results and those of 
Lambrecht (75) it appears likely that there are at least two types of 
receptors.
Following binding of PAF to its receptor there is subsequent 
internalization of the PAF-receptor complex(78), which probably explains 
the rapid desensitization of PAF induced responses in a variety of 
tissues(79,80). Several biochemical changes are known to accompany the 
occupation of PAF-receptors by PAF(Fig 3). There is activation of 
phospholipase C, triggering the degradation of phosphoinositides to 
inosine triphosphate (IP3) and diacylglycerol (DG) both substances are 
known to be able to act as second messengers in bringing about a variety of 
intracellular events (81,82). For instance, DG is able to activate 
proteinkinase C, leading to the phosphorylation of specific intracellular 
protein involved in physiological processes such as secretion or 
contraction(83). IP3 is able to release intracellular Ca++ (84) from internal 
stores which may in turn regulate other intracellular events such as Ca++ 
dependent K+ channels (85). In some cell types such as the human 
platelet, PAF activation will inhibit the formation of cyclic AMP by other 
endogenous agents such as prostaglandins (86). PAF also stimulates cell to 
release free arachidonic acid and metabolize it to eicosanoids, which are 
responsible for some of the actions of PAF (87).
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Protein Kinase C
e.g. phosphorylation of specific  
Intracellular proteins
Figure 3. Interaction of PAF with its putative receptor site results in 
activation of membrane associated phospholipase C, leading to 
stimulation of the phosphotidylinositol(PI) cycle. Inositol triphosphate (IP 
3) and diacylglycerol (DG) are generated from the PI cycle and act as second 
messenger in bringing about an increase in intracellular Ca++ and 
activation of protein kinase C. PAF is suggested to interact with the 
putative receptor at three distinct points in the molecule : A, acetyl group 
at position 2; B, C16-C18 backbone; C, ether link.
Cellu/ar Response
PAF produces acute reversible bronchocostriction in experimental 
animals (88). Repeated aerosol administration of PAF results in 
tachyphylaxis. In man following inhalation by normal healthy volunteers 
(59,60) PAF causes bronchoconstriction with a rapid onset of action (2-3 
min) and a short duration (15-45min).
The mechanism by which PAF produces bronchocostriction is not 
exactly known. Patterson et al (90) have suggested that the 
bronchoconsrtriction caused by PAF in human is mediated at least in part, 
by histamine release not by cholinergic or cyclo-oxygenase dependent 
mechanism. This is partly supported by Chung et al(91) who reported that 
bronchoconstriction caused by PAF is partially inhibited by salbutamol. A 
direct effect of PAF on airway smooth muscle may exist but its importance 
appears to be minor. An indirect effect is mediated via generation of other 
biologically active mediator such as sulphidopeptide leukotrienes (89).
PAF is reported to be one of the most potent agents in inducing 
increased vascular permeability(92) thus causing oedema formation and 
activate inflam matory cells chemotaxis, including platelets(96), 
neutrophils(97), macrophages (98), monocytes (99) and eosinophils(lOO). In 
human skin PAF induces an acute weal and flare response(93) that can be 
potentiated by concomitant administration of vasodilator prostaglandins 
such as PGE 1 (94). The oedema formation seems to be independent of 
cyclo-oxygenase production or histamine, as it cannot be prevented by 
indomethacin or the histamine HI antagonist mepyramine (95). On the 
other hand prior treatment with glucocorticoid significantly reduces the 
oedema formed after intracutaneous PAF infiltration. Following local 
administration of PAF to the skin of normal volunteers there is 
infiltration of inflammatory cells notably neutrophils,4-6 hours after 
treatment and a mixed cellular infiltration comprising neutrophils and 
mononuclear cells at 24 hours(lOl). In contrast local administration of 
PAF to the skin of atopic subjects results in selective eosinophil 
infiltration very reminiscent of antigen induced eosinophil infiltration in 
the same subjects (102).
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CHAPTER THREE
PROJECT
The main aim of this work is as follows
1. To study the bronchoconstrictor effect of Platelet activating factor 
given by inhalation in atopic and nonatopic subjects.
2. To study the effects of Platelet activating factor on bronchial 
responsiveness to methacholine in atopic and nonatopic subjects.
3. Platelet activating factor has been shown to produce bronchial 
hyperresponsiveness both in animals and humans. To determine 
whether this bronchial hyper-responsiveness is reproducible.
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3.1 PLATELET ACTIVATING FACTOR & BRONCHIAL 
HYPERRESPONSIVENESS.
Platelet activating factor is a biologically active inflammatory mediator 
like histamine , prostaglandin & leukotrienes. It has been demonstrated to 
play an important role in allergic diseases(57). Lung seems to be the main 
target organ for its action where it causes bronchoconstriction (91, 103), 
induces bronchial epithelial damage (104) and increases bronchial 
pulmonary vascular permeability. PAF when administered either by 
inhalation  or in travenously  causes increase in bronchial 
hyperresponsiveness (100) which may last from 24 hours to several days. 
Cuss et al (59) have demonstrated increased hyperresponsiveness to 
methacholine in normal subjects for several weeks after PAF inhalation. 
Also Rubin et al (60) has demonstrated an enhanced bronchial reactivity 
in normal subjects but failed to show any increase in bronchial reactivity 
in asthmatics one hour after PAF challenge. Chung and Barnes (105) have 
reported that subjects with mild asthma do respond to PAF inhalation but 
to a similar degree as normal subjects. However several of the subjects did 
have increased reactivity at 3 days post PAF. Though it has been reported 
that PAF does increases bronchial responsiveness to methacholine in 
normal as well as asthmatic subjects, some studies (106,107,108,114) have 
failed to confirm this finding. In this study we have investigated the effect 
of inhaled PAF in inducing bronchial hyperresponsiveness by comparing 
atopic and non-atopic asymptomatic subjects. Furthermore we have 
studied whether this phenomenon is reproducible.
3.2 SUBJECTS.
Thirteen subjects participated in the study which was approved by the 
West of Scotland Hospital Ethical Committee, Western Infirmary 
Glasgow. Written consent was obtained in each case. The subjects were all 
non smokers and were divided into two groups. The first group 
comprised, seven of them, who were atopic. In the second group there 
were six nonatopic healthy volunteers. The atopic subjects were all female 
age 21-38 (average 29. 3 yr), height between 157-169 (average 164 cm) and 
weight 58-68 (average 64. 7 kg). They were all skin tested to standard 
antigens, i. e. , house dust, house dust mites, cat, dog, feather, aspergillus, 
grass, pollens and a negative control. The atopy was defined by a positive
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skin reaction of greater than 3 mm diameter to at least two antigens. The 
atopic subjects were asymptomatic at the time of the study which was 
carried out before the pollen season. The demographic data is given in 
detail in Table 1.
The six nonatopic (negative skin reaction to the above mentioned 
antigens) subjects comprised three males and three females, age 22-38 
(average 29. 7 yr) ; height 163-187 (average 170. 7 cm) and weight (60-73 
average 66. 9 kg). The demographic detail as shown in Table 2.
3.3 CHALLENGE MATERIAL & METHOD
3. 3.1 METHACHOLINE
Methacholine chloride solutions (Sigma Chemical Company Limited , 
Fancy Road Poole Dorset BH17 7NH ) were prepared in phosphate buffer 
saline Ph 7. 4 and stored at -4 C . Before use , solutions were allowed to 
warm to room temperature. Increasing doubling concentrations , ranging 
from o. 0625 mg/ml to 64 mg/ml, were used.
3. 3. 2 NEBULISER
Methacholine solution was given via Wright's nebuliser which is a Jet 
nebuliser driven by compressed air & generating aerosol with a mass 
median aerodynamic diameter between 1 and 5 mm . The aerosol was 
passed directly into a face mask held over the mouth and clipped nose, 
and was inhaled by tidal breathing. The reservoir volume was 3 ml and 
the air flow of 9 L/min (pressure 3. 5 Kpa) delivered an output of
0.13ml/min. With 2 minutes inhalation time using tidal breathing, 0. 26 ml 
was delivered to the mouth. The nebuliser was calibrated by using 3ml of 
normal saline and operated for two total time samples. The output was 
determined by measuring the change in weight using A SARTORIUS 
GMBH GOTTINGEN balance (range 0 to 500 g)
Bronchial responsiveness was calculated from a series of 
methacholine challenge tests, starting with a smallest concentration of 0.
0,0625 m g/m l of methacholine given via the W right's nebuliser. 
Successively greater concentration in two fold increments were used to the 
maximum concentration when SGaw (specific airway conductance ) fell by 
35 % of the lowest post saline starting value. The dose response curve was
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plotted on a semilog paper and the concentration of methacholine that 
decreased SGaw to 35 % (PC 35)was determined by linear interpolation.
3. 3.3 PAF & ITS INHALATION
Synthetic PAF c-16 (Cascade Biochem Limited , The Innovation Centre 
University of Reading Berkshire ) dissolved in chloroform/methanol 
(9:1) and stored at -20 C until required. Just before use 5 mg was dissolved 
in 2. 5 ml of phosphate buffer saline Ph 7. 4 to provide concentration of 
2mg/ml. This solution was given as an aerosol delivered by the Acorn 
nebuliser attached to a dosimeter. This is a breath actuated device 
(Nebuchek P. K. Morgan Gillingham Kent), driven by compressed air at a 
pressure of 2. 5 Kpa and an output of 12 ug/breath 8 successive breaths 
were made and a total PAF dose of 96 ug was inhaled by each subject at one 
sitting. The response to PAF was measured by measuring specific air way 
conductance (SGaw by the Master Lab Body Plethysmography) before and 
at 0,1, 2, 3, 5, 7,10,15, 20, and 45 minutes post PAF challenge.
3. 3. 4 SPECIFIC AIRWAY CONDUCTANCE & BODY 
PLETHYSMOGRAPHY
Plethysmography is the most accurate method of measuring absolute lung 
volume. Plethysmograph (Body Box) also provides a method for 
measuring airway resistance (Raw), which along with pulmonary tissue 
resistance (R ti)and chest wall resistance (R cw), make up the total 
respiratory resistance (RL).
Airway resistance in a normal individual is known to decrease with 
increasing lung volume. To provide a volume standard airway resistance 
measurement, the conductance (Gaw, the reciprocal of resistance ) is 
divided by the TGV (thoracic gas volume) at which the Raw is measured, 
to yield the specific conductance SGaw.
SGaw is expressed as s"  ^Kpa'^ (normal value is 1.12-4. 00 s"^Kpa"^).
Airway resistance can be measured rapidly and non-invasively with 
standard Plethysmographic equipment. We used The MasterLab Body 
Plethysmograph Jaeger (Medical Electronics and Data Processing system, 
Leics) a computerised system working according to the constant volume, 
variable pressure system. It consists of a large chamber, a
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pneumotachograph, and three transducers, which measure changes in the 
box pressure ( A P box), mouth pressure ( A P mo), and flow at the mouth 
(V). It is a very sensitive programme and needs volume and box 
calibration before use.
The subject is seated in a closed chamber breathes through a special 
mouth piece shutter assembly. At the end expiration, the shutter is closed 
to occlude the mouth piece, and the subject is asked to rhythmically 
compress and decompress the thorax by panting lightly against the closed 
shutter. While the shutter is closed, no airflow occurs within the airway, 
so mouth pressure changes (A Pmo) are equal to alveolar changes (A P 
alv). Also during this manoeuvre, the changes in box pressure reflect the 
changes in thoracic volume, and are proportional to the changes in 
alveolar gas pressure. Boyle’s Law (P1V1=P2V2) can be applied to these 
pressure-volume changes to calculate the volume being compressed i. e, 
the subject's thoracic gas volume.
For measurement of airway resistance, the same shallow technique 
is employed, in order to keep the subjects glottis open and prevent 
respiratory temperature artifacts in the box. While the subject pants 
through the open mouth piece , flow at the mouth and corresponding 
cyclical changes in box pressure are recorded. The shutter is then closed 
briefly for TGV measurement. The ratio of alveolar pressure to thoracic 
compression (A Pmo/A P box shutter closed ) is divided by the ratio of 
airflow at the mouth to thoracic compression ( V/ A P box ). The quotient 
represents the airway resistance.
3. 4 PROTOCOL & METHOD
The protocol aimed to examine the effects of inhaled PAF, on the 
bronchial airway responsiveness to methacholine by checking specific 
airway conductance SGaw in the volume constant body plethysmograph 
and to see whether this phenomenon was reproducible in atopic and 
nonatopic subjects.
This involved three cycles at least four weeks apart in both groups. 
Each cycle consisted of three to five visits each lasting for about 45 
minutes. At the beginning of each cycle a baseline bronchial 
responsiveness was performed by giving doubling concentration of 
methacholine chloride calculating the PC 35 i. e. , the concentration of
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methacholine at which the SGaw (specific airway conductance) falls by 35 ,
%. On^next day a fixed dose of 96 ug PAF was given by Acorn nebuliser as 
explained in the previous section. Specific airway conductance (SGaw) was 
measured by the plethysmograph before and at 0, 2, 3, 5, 7, 10, 15, 20, and 
45, minutes after PAF inhalation. 24 hours later i. e. , On 1st post PAF day, 
bronchial airway responsiveness was measured by methacholine 
challenge test. The same challenge test was repeated on^rd  post PAF day,
7th post PAF day and so on until the bronchial reactivity to methacholine 
came back to baseline level. PAF challenge and methacholine 
responsiveness was repeated on 2 occasions allowing at least 4 weeks 
between cycles. (Table 3)
3. 5 STATISTICAL ANALYSIS.
All values are listed as mean and standard error of the mean(sem) unless 
stated as G Mean (geometric mean). The analysis was performed by the 
Minitab Statistics System Fundamental version. The PC 35 value was 
calculated by computerised programme for PC. The comparison between 
Pre PAF and Post PAF was performed by paired t test and a p value of < 0.
05 was considered to be statistically significant.
3. 6 RESULTS:
3. 6.1 PAF CAUSES BRONCHOCONSTRICTION IN BOTH ATOPIC AND 
NONATOPIC SUBJECTS.
PAF when given by inhalation in a fixed dose of 96 ug caused marked 
bronchoconstriction in both atopic and non atopic subjects, in each PAF 
day of the three cycles. The maximum mean(sem) percentage falls in 
SGaw from post saline baseline value in nonatopic subjects (Table 4) were 
47. 3 (8. 67), 49. 5 (9. 26), and 47. 17 (8. 19) in the three cycles respectively. 
(Fig. 4) There was no significant difference between the three cycles, 
suggesting that the PAF was equally effective in all cycles. The mean 
baseline SGaw in the same subjects on the study days of the three cycles 
(Table 5. 1, 5. 2, 5. 3) were comparable with no statistically significant 
difference (Figure 5.1, 5. 2, 5. 3).
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A similar response to PAF was also seen in the atopic subjects with 
the maximum mean (sem) percent fall in SGaw 41. 7 (6. 15), 48. 0 (6. 12) 
and 49. 29 (6. 33) respectively in the three cycles (Table 6) and (Fig. 6).
The mean Pre and Post saline baseline SGaw on the Methacholine 
challenge days were comparable and there was no significant difference 
(Table 7. 1, 7. 2, 7. 3), (Figure. 7. 1, 7. 2, 7. 3). Subjectively both atopic and 
nonatopic subjects who had shown a significant fall in SGaw also became 
wheezy. Two of the nonatopic subjects who were less wheezy were 
moderately flushed after PAF inhalation. After PAF inhalation neither 
atopic nor nonatopic subjects developed excessive airway secretions. Other 
characteristics of the aerosolised PAF included a rapid onset of action (1-3 
min) and short duration (15-45 min).
3. 6. 2 EFFECT OF PAF ON METHACHOLINE RESPONSIVENESS:
There was no statistically significant difference between the mean PC 35 
SGaw Methacholine before and after PAF challenge on day 1, day 3 and day 
7 in the three cycles in nonatopic subjects (Table 8. 1, 8. 2, 8. 3)). However 
two subjects( JM Figure 8. 1, DS Figure 8. 5) of the nonatopic healthy 
volunteers did show increased bronchial responsiveness( Fig. 8).
Amongst the atopic asymptomatic subjects there was no statistically 
significant difference in PC 35 SGaw of methacholine before and after PAF 
challenge on day 1, day 3 and day 7 of the three cycles (Table 9.1,9. 2,9. 3).
subject (CJ) show some increase bronchial responsiveness 
(Figures. 9.1-9. 7).
The mean baseline SGaw and geometric mean PC35 SGaw 
Methacholine before and after PAF challenge on the study days of the 
three cycles in both nonatopic (Table 12) and atopic (Table 13) subjects were 
comparable. The PC35 SGaw Methacholine in the three cycles in nonatopic 
subjects were 6. 51, 8. 16 and 8. 1 respectively. The PC35 SGaw 
methacholine in the three cycles of atopic subjects were o. 99, 0. 67 and 1. 
15 respectively. These values were much smaller than that of nonatopic 
subjects. This suggests that bronchial airway in atopic subjects is more 
hyper-responsive to methacholine than nonatopic subjects(109,110).
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3. 6. 3 WHETHER BRONCHIAL AIRWAY RESPONSIVENESS IS 
REPRODUCIBLE?
Our study failed to show statistically significant increase in bronchial 
responsiveness to methacholine after PAF challenge. However the two 
nonatopic subjects (JM, DS), who showed a moderate degree of increase 
(<2 fold increase) in bronchial responsiveness in the two cycle, the 
temporal relationship in the subsequent cycles was not clear (Fig. 8. 1, 8. 5)
3.7 DISCUSSION.
Although the aetiology of increased bronchial responsiveness is not well 
defined, its presence as a component of clinical asthma is firmly 
established . It has also been established that changes in airway reactivity, 
either through seasonal allergen exposure or when attenuated by 
therapy(115), are closely related to the clinical expression of asthma. What 
is not certain, however, is what mediators are involved in the increase in 
nonspecific airway responsiveness. Recent evidence has given PAF as a 
unique role in this regard.
Cuss et al(59) have suggested that PAF may be involved in the 
changes in bronchial responsiveness. They demonstrated enhanced airway 
responsiveness in normal subjects for several weeks after PAF inhalation. 
This was in part confirmed by Rubin et al(60) who reported an increase in 
bronchial airway responsiveness in normal subjects, but not asthmatics 1 
hour after PAF challenge. Although nonspecific bronchial responsiveness 
is increased in normal subjects, the fact that Rubin et al showed that 
asthmatic patients did not have increased bronchial responsiveness 
following PAF inhalation makes it unique as a mediator. All other known 
mediators cause immediate bronchoconstriction in asthmatic patients but 
in few normal subject. Importantly it has been reported to induce increase 
in nonspecific bronchial airway responsiveness, but mainly in 
nonasthmatic subjects. Stenton et al (113) also reportedjncrease in airway 
responsiveness following PAF inhalation,which wevg poorly sustained 
and not reproducible.
Our study showed contrasting evidence to the concept that PAF can 
increase bronchial responsiveness in normal subjects, as shown by Cuss et 
al (59) and Rubin et al (60). The fact that PAF inhalation had no effect on
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bronchial airway responsiveness in our study supports the finding of 
Russell et al (107), Hopp et al (108), Jenkins et al (111) and Lai et al (114)
It is not known , however , if there is a threshold dose of inhaled 
PAF necessary to induce changes in airway responsiveness. For their study 
Russell et al (107) used five breaths of 200mg/L(30 ug delivered), Cuss et al 
(59) used a mean dose of inhaled PAF of 60 ug (27. 5-145 ug), given as five 
single breaths over 1 hour. Rubin et al(60) used a single breath of 1000 
ug/L  (delivered a dose of 23 ug). In our study all subjects inhaled eight 
breaths of 200mg/L (96 ug delivered). The difference in the results is not 
likely to be due to a discrepancy in the amount of inhaled PAF, as the dose 
was sufficient to cause marked bronchoconstriction. A recent report by 
Wardlaw et al (112) suggests that larger doses of inhaled PAF then used 
may be necessary to induce changes in nonspecific airway responsiveness.
It is also important to know that in the studies of Cuss et al( used 
pFEF 60-80 %) and Rubin et al(used SGaw & Vp30), the workers used a 
measurement of minimal changes in airway calibre to determine the 
changes in airway responsiveness. This is necessary because normal 
subjects often do not have marked changes to methacholine using the 
measurement of forced expiratory volume in one second. We used SGaw 
to measure the airway responsiveness and a similar measurement was 
used by Rubin et a l . Although these tests are very similar, they also have a 
larger variability than FEV1.
Patient selection is another variable to be considered. All subjects 
studied by Cuss et al showed bronchoconstriction after PAF inhalation, 
with a greater than 40 % fall in Vp30. It is not clear whether their subjects 
were selected using these criteria. It is probable that not all subjects are 
similar in their response to PAF. The normal subjects studied by Rubin et 
al were less bronchial responsive to PAF compared to the subjects used by 
Cuss et al. It is conceivable that subjects with large airway response are 
more likely to have a prolonged change in airway responsiveness.
Our results on inhaled PAF in atopic subjects support the work of 
Rubin et al who failed to show an increase in bronchial responsiveness in 
asthmatics, 1 hour after PAF challenge. Chung and Barnes(115) have 
recently reported that in eight mild asthmatics there was no increase in 
airway responsiveness as a group, up to seven days following PAF
A j i ^ i
inhalation ^ were , however , selected asthmatic subjects who did have
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increased airway responsiveness. In our study occasional atopic subjects 
had a moderate increase in bronchial airway responsiveness on post PAF 
day 1 and day 3 but a temporal relationship in subsequent cycles was less 
clear.
Airway hyperresponsiveness and airway eosinophilia are hallmarks 
of asthma. The study of PAF. induced bronchial hyperresponsiveness may 
give further insight into the pathogenesis of asthma,as PAF has many 
properties that make it a mediator of interest in the aetiology of asthma. 
The studies so far showed that inhaled PAF no doubt causes 
bronchconstriction but opinion still differs whether it cause increase 
bronchial airway hyperresponsiveness. Clearly further studies are required 
to clarify the potential role of PAF in the pathogenesis of 
hyperresponsiveness and to determine why there is difference in the 
results between various studies in this effect of PAF in normal healthy 
people,despite showing similar bronchoconstriction and cardiovascular 
responses. Also studies are needed to address the question whether the 
hyperresponsiveness is reproducible. Whatever conclusion is drawn from 
PAF challenge studies, its role in the pathogenesis of bronchial 
hyperresponsiveness and asthma awaits the bio-availability of potent PAF 
antagonist for clinical trials. It will then be possible to determine if specific 
PAF antagonist can inhibit specific allergens induced responses in the 
airway and increased reactivity resulting from such allergen challenge. 
Also their effects in clinical asthma can be assessed.
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PART TWO
Aim: Platelet activating factor is a highly active mediator which has been 
implicated in allergic inflammation and bronchial asthma, possibly 
by interacting with eosinophils.
Eosinophils cause damage to the lung by releasing various proteins 
including eosinophilic cationic protein (ECP). Sputum levels of 
ECP have a positive correlation with the severity of the damage 
caused.
Whether measurement of the ECP in the serum has the same 
significance, is examined in the second part of the study.
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CHAPTER FOUR.
SERUM EOSINOPHILIC CATIONIC PROTEINS IN NONATOPIC
SUBJECTS BEFORE AND AFTER CHALLENGE.
4.1. INTRODUCTION OF E. C. P.
The eosinophil was probably first observed in peripheral blood of humans 
in 1846 by Wharton Jones, an anatomist at Charing Cross Hospital. But it 
was Paul Ehrlich who discovered the best known characteristics of the cell. 
In 1879, Ehrlich described a leucocyte that avidly bound acidic dyes (116). 
He called this cell eosinophil because of the intense avidity of its granules 
for eosine, a brominated fluorescine derivative.
The presence of high numbers of eosinophils in diseases associated 
with parasite infection led to the widespread believe that the cell plays a 
unique and beneficial role in host defense against such organism. 
Eosinophils accumulate about parasites in vivo and deposit toxic granules 
contents on them (117). Both eosinophil granule proteins and oxygen 
metabolite have been shown to kill parasite worms(118). Similarly the 
high number of eosinophils in allergic diseases such as asthma coupled 
with knowledge that eosinophils associated enzymes can metabolize 
mediators of anaphylaxis including LTC4, histamine and platelet 
activating factor, led to the suggestion that one function of eosinophil was 
down regulation of the inflam m ation after im m ediate type 
hypersensitivity reaction (119). However as the knowledge of the toxicity 
of eosinophil to human tissue developed over the past decade, the view of 
the role in asthma changed. The eosinophil are now regarded by many as a 
potent pro-inflammatory cell with considerable tissue injuring potential 
and a primary mediator of epithelial injury and bronchial hyper-rectivity 
(120).
Eosinophils are rarely found in the normal human lower 
respiratory tract (121). However many inflammatory disorders of the lower 
respiratory tract are associated with an accumulation of eosinophils in the 
parenchyma. Eosinophil activity appears to be part of the inflammatory 
process in hypersensitivity pneumonitis histiocytosis X, eosinophilic 
pneumonia, idiopathic pulmonary fibrosis, sarcoidosis and the interstitial 
diseases associated with collagen-vascular or drug induced disorders (121,
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122). Eosinophilia in bronchoalveolar lavage may be a marker of 
progressive lung damage in patients with idiopathic pulm onary 
fibrosis(123, 124). Eosinophil activation in the lung has also been related to « 
the lung damage in adult respiratory distress syndrome(125). Rower and 
Colleagues(126) professed that activated eosinophils caused acute 
oedematous injury in isolated perfused rat lungs. Fujimoto and Co­
worker (127) report on studies in a similar model that also involves the 
eosinophils participation in the production of microvascular injury. 
Activated eosinophils caused a biphasic pulmonary vascular response, an 
initial intense vasoconstriction was followed by increased pulmonary 
microvascular permeability that resulted in lung oedema.
How is the lung injury caused by the eosinophils and what process 
is involved to mediate lung injury?It is the identification and isolation of 
several highly cytotoxic secretory proteins, from the eosinophils(128, 129) 
which is mainly responsible for the tissue damage. The observation in 
several studies have shown a direct correlation between eosinophil 
number and activity on one hand and the severity of the disease such as 
asthma on the other(130-133)
Morphologically the human eosinophil is characterised by its 
content of eosine staining granules, some of which contain typical 
crystalloid formations, visible by electron microscopy. The granules 
contain four major proteins(128, 129), The eosinophil cationic 
proteins(ECP), Eosinophil peroxidase(EPO), Eosinophil protein X or 
eosinophil derived neurotoxin and major basic proteins make up to 90 % 
of all granule proteins. The major basic protein makes up the crystalloid in 
the granules, whereas the other proteins are located in the matrix of the 
granules . A further protein has been purified from human eosinophils 
(134-136). This protein is mainly found in the plasma membrane and 
forms the Charcot-Leyden crystals in tissue.
Eosinophils are one of the important cell type in asthma.When stimulated 
these cells produce several toxic proteins including major basic protein 
and eosinophilc cationic protein (ECP).In a recent study it has been 
reported that increased numbers of eosinophils are associated with
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increasing severity of asthma.Furthermore ECP levels in bronchoalveolar 
lavage fluid is associated with the severity of symptoms(139).It has also 
been demonstrated that asthmatics with sputum eosinophilia are 
associated with increased levels of ECP in the sputum,thus measuring ECP 
in sputum is a good index of assessing the severity of asthma.This study 
was arranged to establish whether Inhaled PAF would have any effect on 
serum ECP levels in atopic and non-atopic subjects.
4.2 SUBJECTS DETAIL
Eight atopic and seven non-atopic asymptomatic subjects participated in 
this part of the study.The protocol was approved by the West of Scotland 
Hospital Ethical Committee Western Infirmary Glasgow.Written consent 
was obtained.All subjects were skin tested.
4.3 METHOD
The study was carried out concurrently with the PAF study previously 
described.Thirteen of the fifteen subjects (6 atopic & 7 non-atopic) were 
concurrent to both studies and 2 more atopic subjects were
recruited.One visit to hospital was involved.Blood samples were taken 
during the first visit before and at 15, 30, 60, 120, and 180 minutes after a 
fixed dose of 96 ug of PAF was inhaled via Acorn nebuliser.Blood samples 
were collected by venepuncture and allowed to stand to clot at room 
temperature for 60 minutes.Serum was separated by centrifugation twice 
at 13050 g for 10 minutes.The sample was then stored at -20 C for analysis 
in batches.
The analysis was done by Pharmacia ECP RIA (Radioimmunoassay of 
eosinophil cationic protein).Pharmacia ECP RIA is a double antibody 
radioimmunoassay.In this process ECP in the sample competes with a 
fixed amount of 125-1 labelled ECP for binding sites of specific 
antibody.Bound and free ECP are separated by the addition of a second 
antibody immunosobent followed by centrifugation and decanting.
The radioactivity in the pellet is then measured and is inversely 
proportional to the quantity of ECP in the sample.
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4.3.1 REAGENTS
Each package of Pharmacia ECP RIA contains reagents for 50 assay tubes, 
sufficient for 19 samples and one standard curve in duplicate.
All reagents are ready for use and should be stored at 2-8 C until the expiry 
date on the labels.
Standard ECP (human) O ug/1, 5 ml 1 vial
2; 5; 15; 100; 200 ug/ml, 0.5 ml each 5 vials
Anti ECP (anti-serum raised in rabbit) 3 ml 1 vial
colour coded yellow
ECP 125112ug, 43.7kbq (1.2 uci) 1 vial
at date of manufacture, 3 ml 
colour coded blue
Decanting suspension 1 vial
(sepharose anti-rabbit IgG raised in sheep), 220 ml 65
4.3.2 TEST PROCEDURE :
Assay standards, control sera and unknowns in duplicate. Prepare a 
standard curve on each assay unit.
4.3.3 WORKING STEPS
UNKNOWNS/CONTROL STEPS STANDARDS
1. Standards 50 ul
2. Unknown sample or control - 50 ul
3. ECP 125-1 (c.Coded Blue) 50 ul 50 ul
4. Anti-ECP(c.Coded Yellow) 50 ul 50 ul
CHECKPOINT content of all tubes should now be green.
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5. Shake the rack to ensure mixing. Incubate for 3 hours at room
temperature.
6. Decanting suspension 2 ml 2 ml
SHAKE THE VIAL TO MAKE THE SUSPENSION HOMOGENEOUS 
BEFORE USE
7. Incubate for 1/2 hour at room temperature.
8. Centrifuge for 10 minutes at 1500 * g.Decant the tubes immediately
in one movement and let stand for 1/2 minute upside down on 
absorbent paper.
9. Determine the radioactivity.
CALCULATION OF RESULTS:
The result were calculated by a computerised programme called 2+2 
logistic programme.
4.4 RESULTS:
The average ECP levels in non-atopic subjects before PAF challenge with 
mean (sem) was 8.3 (3.6) while the levels at 15, 30, 60, 120, and 180 minutes 
post PAF challenge were 5.4 (2.1), 5.6 (1.3), 5.7 (1.2), 5.6 (1.2), and 4.6 (0.97) 
ug/L (Table 10) respectively.There was no statistically significant difference 
in serum ECP levels before and after PAF inhalation.There were great 
individual variations in the ECP levels the highest being 28 and the lowest 
as 2.4 ug/L(Figure 10).
Amongst the atopic subjects the mean serum ECP level before PAF 
challenge mean(sem) was 4.9(0.7), while the mean(sem) levels at 15, 30, 60, 
120, and 180 minutes post PAF challenge were 3.5(1.0), 4.6(0.7), 4.2(0.7), 
4.6(0.9), and 4.6(0.9) ug/L(table 11) respectively.There was no statistically 
significant difference in serum ECP levels before and after PAF inhalation 
(Figure 11).
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4.5 DISCUSSION:
PAF is a highly active mediator which has been implicated in allergic 
inflammation and asthma, possibly by interacting with eosinophils. 
Eosinophils can cause damage to lung tissue by releasing various proteins 
including ECP. The ECP has shown a positive correlation with late 
response after allergens challenge in asthma. It has been suggested that 
measurement of ECP may be used to predict the occurrence of a late 
asthmatic reaction(137)
A relation between airway hyper-responsiveness and activity of 
eosinophils is suggested by a study(137) in atopic subjects with seasonal 
allergic symptoms.In these patients there was a correlation between the 
rise in serum ECP concentration during pollen season and increased 
airway responsiveness(138).In the same study a group treated by 
immunotherapy had no changes in serum ECP levels and less 
responsiveness.Recently raised ECP levels in sputum  has been 
demonstrated in asthmatics who had sputum eosinophilia(139), thus 
suggesting the importance of ECP levels in bronchoalveolar lavage 
fluid.This is an invasive procedure and is not always feasible.To see 
whether relatively easier measurement of ECP levels in blood serve the 
same purpose, we conducted this study to measure ECP levels in serum 
before and after PAF challenge up to three hours.We failed to show any 
significant change after PAF challenge in either atopic or non-atopic 
subjects studied up to three hours post PAF inhalation.lt is possible that 
PAF may not be effective on the circulating eosinophils.This study 
suggested that serum ECP level is not a good index for assessing the effect 
of PAF on bronchial airway.A recent study by Mokte et al(140) also 
suggested that sputum ECP level and blood eosinophils may be more 
useful markers of expiratory lung flows than serum ECP in patients with 
chronic bronchial asthma.The importance of ECP in clinical practice needs 
further evaluation.
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Name Age Sex Height Wt Skin test
(yrs.) (cm) (kg) (+  to)
SG 32 F 168 64 Pol.HD.
MW 21 F 158 6 HD. Pol.Cat.Flower
JS 28 F 164 65 Cat. HD.
CR 38 F 165 66 HD.Cat.Pol.
CJ 31 F 167 68 Cat.Gr.Fea.H.D.M.Pol
MM 27 F 169 64 HDM.Gr.Hors.Cat.Asp.Pol
LM 28 F 157 58 Gr.HD.Fea.
Mean 29.3 164 64.7
HD  =  House dust Pol =  Pollen HDM  =  House dust mites
Gr =  Grass Asp =  Aspergillous Fea =  Feather
TABLE 1. The dem ographic data  of the atopic subjects
( i )
Name Age
(yrs.)
Sex Height
(cm)
Skin test
JM 38 F 170 -
EH 34 F 166 -
CO 22 M 170 -
JJ 27 F 163 -
DS 21 M 187 -
Ml 36 M 168 -
Mean 29.7 170.7
_  -  f V E G A T i v t -
TABLE 2. Demographic data of the nonatopic subjects
( i i )
Study day PAF Inhalation Methacoline Challenge
1 - +
2 + -
3 - Post PAF Day 1 +
5 - Post PAF Day 3 +
9 - Post PAF Day 7 +
12 - Post PAF Day 10 +
+ / -  = M ethacoline or PAF challenge given/not given
TABLE 3. Showing detail about the protocol of PAF project
( i i i )
Name CYCLE 1 CYCLE 2 CYCLE 3
JM 41 37 39
JJ 68 74 62
EH 20 27 26
CO 70 65 70
DS 58 70 62
Ml 27 24 24
Mean 47.3 49.5 47.3
(sem) 8.67 9.29 8.19
TABLE 4 MAXIMUM PERCENTAGE FALL IN SGaw AFTER PAF CHALLENGE
IN EACH OF THE THREE CYCLES IN NON-ATOPIC SUBJECTS
( i v )
Pre PAF Post PAF
Name D1 D2 D3
JM 1.54 1.34 1.29 1.24
JJ 1.52 1.46 1.87 1.90
EH 1.42 1.22 1.33 1.34
CO 1.45 1.54 1.32 1.39
DS 1.31 1.34 1.34 1.29
Ml 1.32 1.43 1.39 1.36
Mean 1.42 1.39 1.42 1.42
sem 0.03 0.04 0.09 0.098
TABLE 5.1 BASELINE SGaw IN NON-ATOPIC SUBJECTS ON
STUDY DAYS OF THE FIRST CYCLE.
(V)
Pre PAF Post PAF
Name D1 D2 D3
JM 1.36 1.47 1.43 1.67
JJ 1.90 1.69 2.00 1.85
EH 1.34 1.23 1.22 1.32
CO 1.39 1.66 1.29 1.52
DS 1.29 1.61 1.09 1.27
Ml 1.36 1.38 1.27 1.22
Mean 1.44 1.51 1.38 1.47
sem (0.09) (0.07) (0.13) (0.10)
TABLE 5.2 BASELINE SGaw IN NON-ATOPIC SUBJECTS ON
STUDY DAYS OF THE SECOND CYCLE.
(Vi)
Pre PAF Post PAF
Name D1 D2 D3
JM 1.67 1.58 1.39 1.39
JJ 1.85 2.09 1.89 1.66
EH 1.32 1.22 1.11 1.15
CO 1.52 1.61 1.62 1.5
DS 1.27 1.36 1.14 1.41
Ml 1.22 1.23 1.66 1.42
Mean 1.47 1.51 1.46 1.42
sem (0.10) (0.13) (0.13) (0.068)
TABLE 5.3 BASELINE SGaw IN NON-ATOPIC SUBJECTS ON
STUDY DAYS OF THE THIRD CYCLE.
(Vii)
Name CYCLE 1 CYCLE2 CYCLE3
CJ 50 45 42
SM 42 50 60
MM 27 65 48
JS 16 16 24
MW 42 44 40
CR 49 62 54
LM 66 54 77
Mean 41.7 48 49.3
(sem) (6.15) (6.12) (6.33)
TABLE 6. MAXIMUM PERCENTAGE FALL IN SGaw AFTER PAF CHALLENGE
IN EACH OF THE THREE CYCLES IN ATOPIC SUBJECTS.
( v i i i )
Name Pre PAF Post PAF
D1 D3 D7
CJ 1.24 1.55 1.61 1.30
SM 1.45 1.00 0.82 0.89
MM 0.74 0.75 1.76 0.67
JS 1.82 1.76 1.79 1.79
MW 0.72 0.78 1.26 0.91
CR 1.13 1.26 1.19 1.29
LM 0.67 0.72 0.69 0.93
Avg 1.11 1.12 1.16 1.11
sem (0.16) (0.156) (0.16) (0.14)
TABLE 7.1 BASELINE SGaw IN ATOPIC SUBJECTS ON
STUDY DAYS OF THE FIRST CYCLE.
( i x )
Name Pre PAF Post PAF
D1 D3 D7
CJ 1.30 1.35 1.31 1.39
SM 0.89 1.20 1.28 1.49
MM 0.82 1.15 0.94 0.72
JS 1.79 1.40 1.78 2.10
MW 0.90 0.85 0.67 1.09
CR 1.29 1.39 1.13 1.20
LM 0.93 0.64 0.99 0.80
Avg 1.13 1.14 1.15 1.25
sem (0.13) (0.11) (0.13) 90.17)
TABLE 7.2 BASELINE SGaw IN ATOPIC SUBJECTS ON
STUDY DAYS OF THE SECOND CYCLE.
( * )
Name Pre PAF Post PAF
D1 D3 D7
CJ 1.39 1.46 1.29 1.45
SM 1.49 1.36 1.36 1.24
MM 0.72 0.75 0.68 1.18
JS 2.10 2.24 1.84 1.73
MW 1.09 0.99 0.99 1.16
CR 1.20 1.39 1.26 1.39
LM 0.80 0.63 0.80 0.64
Avg 1.25 1.26 1.17 1.25
sem (0.17) (0.20) (0.15) (0.13)
TABLE 7.3 BASELINE SGaw IN ATOPIC SUBJECTS ON
STUDY OF THE THIRD CYCLE.
( x i )
Name Pre PAF Post PAF
D1 D3 D7
JM 3.2 2.2 2.7 2.8
JJ 4.3 9.9 6.8 4.3
EH 9.7 14.1 8.3 22
CO 3.9 3.7 4.1 5.5
DS 5 3.6 5.4 5.5
Ml 29.5 23.9 28.4 24.2
G.Mean 6.51 6.79 6.76 7.6
TABLE 8.1 PC 35 SGaw BEFORE AND AFTER INHALATION
IN NON-ATOPIC SUBJECTS IN THE FIRST CYCLE.
p > 0 . 0 5  NS
( x i i )
Name Pre PAF Post PAF
D1 D3 D7
JM 4.3 3.4 3.9 4.8
JJ 4.3 7.9 4.5 3.2
EH 22 24.1 12.6 10.5
CO 5.5 4.6 6.6 3.04
DS 5.5 3.2 6.4 5.6
Ml 24.5 30 17 25.8
G.Mean 8.16 8.1 7.36 6.42
TABLE 8.2 PC 35 SGaw BEFORE AND AFTER PAF INHALATION
IN NON-ATOPIC SUBJECTS IN THE SECOND CYCLE.
p > 0 . 0 5  NS
( x i i i )
Name Pre PAF Post PAF
D1 D3 D7
JM 4.8 3.4 3.7 5.7
JJ 8.4 4.2 4.01 3.7
EH 10.5 9.3 10.5 11
CO 4.6 4.3 4.03 5.9
DS 5.6 3.9 3.4 4.3
Ml 25.8 27.1 31.1 28.2
G.Mean 8.1 6.3 6.4 7.4
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TABLE 8.3 PC 35 AGaw BEFORE AND AFTER PAF INHALATION
IN NON-ATOPIC SUBJECTS IN THE THIRD CYCLE.
p > 0 . 0 5  NS
( x i v )
Name Pre PAF Post PAF
D1 D3 D7
CJ 3.8 3.4 2.3 4.4
SM 2.6 4.7 3.8 6.4
MM 0.9 1.3 2.3 0.8
JS 2.9 2.8 3.9 2.6
MW 0.4 0.3 0.1 0.3
CR 0.3 0.5 0.3 0.4
LM 0.3 0.1 0.3 0.13
G.Mean 0.99 0.98 0.95 0.99
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TABLE 9.1 PC 35 ^Gaw BEFORE AND AFTER PAF INHALATION
IN ATOPIC SUBJECTS IN THE FIRST CYCLE OF THE 
STUDY DAYS.
p > 0 . 0 5  NS
( X V )
Name Pre PAF Post PAF
D1 D3 D7
CJ 2.8 2.8 3.5 3.8
SM 2.5 4.1 2.8 2.6
MM 0.9 1.3 0.7 0.5
JS 1.3 1.5 1.9 2.9
MW 0.2 0.2 0.4 0.4
CR 0.3 0.65 0.42 0.32
LM 0.13 0.12 0.08 0.33
G.Mean 0.67 0.86 0.78 0.89
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TABLE 9.2 PC 35 yjlGaw BEFORE AND AFTER PAF INHALATION
IN ATOPIC SUBJECTS IN THE SECOND CYCLE OF THE 
STUDY DAYS.
p > 0 . 0 5  NS
( x v i )
Name Pre PAF Post PAF
D1 D3 D7 D10
CJ 4.4 4.5 3.1 4.5
SM 6.4 4.6 2 1.6 2.99
MM 0.8 0.4 0.2 0.5
JS 2.6 2.9 3.8 3.4
MW 0.3 0.1 0.1 0.4
CR 0.4 0.31 0.14 0.2 0.38
LM 0.13 0.1 0.4 0.1
G.Mean 1.15 0.79 0.75 0.89
TABLE 9.3 PC 35 #Gaw BEFORE AND AFTER PAF INHALATION
IN ATOPIC SUBJECTS IN THE THIRD CYCLE OF THE 
STUDY DAYS.
p > 0 . 0 5  NS
( x v i i )
Pre PAF Post PAF
Name +15 min +30 min +60 min +120 min +180 min
JM 2.4 2.6 2.2 2 3 3
JJ 0 ND 2.2 3.2 2.4 2.2
EH 2.6 3.2 3.2 2.6 3.2 1.8
CO 9 7 7 10 6 5
DS 28 17 10 8 10 8
RJ 6 4 4.5 6 4.5 4.5
CD 10 4 10 8 10 8
Mean 8.3 5.4 5.6 5.7 5.6 4.6
(sem) (3.6) (1.3) (1.3) (1.18) (1.22) (0.97)
TABLE 10. SERUM EOSINOPHILIC CATIONIC PROTEIN LEVELS IN
NON-ATOPIC SUBJECTS BEFORE AND AFTER PAF INHALATION.
p > 0 . 0 5  NS
( x v i i i )
Pre PAF Post PAF
Name +15 min +30 min +60 min +120 min +180 min
CJ 8.5 8.5 8 8.5 8.5 10
SM 3 3.2 3.2 3.2 3.2 1.8
MM 6 ND 6.5 6 5.5 5
JS 2.6 ND 2.4 2.6 2.6 3
MW 5.5 4.5 4.5 4 3.2 5
CR 6 6 5 4 7 6
IP 3.2 2.2 3 3 3 2.4
AJ 4.5 3.6 4.5 2.6 4 4
Mean 4.9 3.5 4.6 4.2 4.6 4.6
(sem) (0.70) (1.0) (0.66) (0.72) (0.76) (0.91)
TABLE 11. SERUM EOSINOPHILIC CATIONIC PROTEIN (ECP) LEVELS IN 
ATOPIC SUBJECTS BEFORE AND AFTER PAF INHALATION.
p > 0 . 0 5  NS
( X X )
Pre PAF Post PAF
D1 D3 D7
CYCLE 1
Mean Base line SGaw 1.42 1.39 1.42 1.42
(sem) (0.03) (0.04) (0.09) )0.09)
PC 35 SGaw (mg/ml) 6.51 6.79 6.79 7.6
CYCLE 2
Mean Base line SGaw 1.44 1.51 1.38 1.47
(sem) (0.09) (0.07) (0.13) (0.10)
PC 35 SGaw (mg/ml) 8.16 8.1 7.36 6.42
CYCLE 3
Mean Base line SGaw 1.47 1.51 1.46 1.42
(sem) (0.10) (0.13) (0.13) (0.07)
PC 35 SGaw (mg/ml) 8.1 6.3 6.4 7.4
TABLE 12. MEAN BASE LINE SGaw AND PC 35 SGaw BEFORE AND
AFTER PAF INHALATION IN NON-ATOPIC SUBJECTS 
ON STUDY DAYS OF THE THREE CYCLES.
p > 0 . 0 5  NS 
( x ix )
Pre PAF Post PAF
D1 D3 D7
CYCLE 1
Mean Base line SGaw 1.11 1.12 1.16 1.11
(sem) (0.16) (0.15) (0.16) (0.14)
PC 35 SGaw (mg/ml) 0.99 0.98 0.95 0.99
CYCLE 2
Mean Base line SGaw 1.13 1.14 1.16 1.25
(sem) (0.13) (0.11) (0.13) (0.17)
PC 35 SGaw (mg/ml) 0.67 0.86 0.78 0.89
CYCLE 3
Mean Base line SGaw 1.25 1.26 1.17 1.25
(sem) (0.17) (0.020) (0.15) (0.13)
PC 35 SGaw (mg/ml) 1.15 0.79 0.75 0.89
TABLE 13 MEAN BASE LINE SGaw AND PC 35 SGaw BEFORE AND
AFTER PAF INHALATION IN ATOPIC SUBJECTS 
ON STUDY DAYS OF THE THREE CYCLES.
p > 0 . 0 5  NS
( x x i )
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